News & Updates

Treatment with zongertinib in Asian patients with advanced HER2-mutant nonsmall cell lung cancer (NSCLC), who have received prior systemic therapy, delivers robust efficacy and elicits an acceptable safety profile, consistent with the overall global analysis, reports a China study.

Asthma and allergic tendency in mothers appear to elevate the risk of congenital heart defect (CHD) in their children, suggests a study, noting that nonallergic asthma also contributes to such risk.

A retrospective study spanning 25 years has shown that intravenous (IV) iron therapy in hospitalized patients with iron-deficiency anaemia and acute infections is associated with a lower risk of death.

In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).